Health Condition 1: A305- Lepromatous leprosy
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
AIIMS Patna
Eligibility
Inclusion criteria
Inclusion criteria: : All patients with Type II lepra reaction age more than 18 years who are attending the Department of Dermatology and receiving Tofacitinib as adjuvant to Prednisolone during the study period. - Patients with Type II lepra reaction age more than 18 years who have received Thalidomide as adjuvant to Prednisolone previously in 2022-23 as available in our department register will also be included in comparison group.
Exclusion criteria
Exclusion criteria: Patients having any active infection or URTI or Diarrhea Immunocompromised status like HIV/Chemotherapy/Radiotherapy Breastfeeding women Severe liver disease or Renal Disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse Rate ENL severity score comparisonTimepoint: At Baseline, 1 month, 3 month and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events DLQITimepoint: At Baseline, 1 month, 3 month and 6 months | — |
Countries
India
Contacts
Public ContactDr Rishav Sanghai
AIIMS Patna
Outcome results
None listed